[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Grand Rounds
Clinician's Corner
October 20, 2004

Antiplatelet Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes

Author Affiliations
 

Grand Rounds at The Johns Hopkins Bayview Medical Center Section Editors: David B. Hellmann, MD, Charles Weiner, MD, Stephen D. Sisson, MD, The Johns Hopkins Hospital, Baltimore, Md; David S. Cooper, MD, Contributing Editor, JAMA .

 

Author Affiliation: Coronary Care Unit, The Johns Hopkins Hospital, Baltimore, Md.

JAMA. 2004;292(15):1875-1882. doi:10.1001/jama.292.15.1875
Abstract

Acute coronary syndromes are a frequent cause of hospital admission for patients with coronary artery disease. The pathophysiology of acute coronary syndromes often involves plaque rupture or fissure with platelet aggregation. Recognition of the importance of platelet aggregation resulted in several large randomized trials testing 3 types of platelet antagonists, aspirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors. A thorough understanding of the data, risks, and benefits of these therapies is important to optimize treatment of the patient with an acute coronary syndrome. Recognition that there is a great deal of interpatient variability in response to these antiplatelet therapies highlights the need for future research in this area.

×